ADAC postpones release of Q2 numbers
Nuclear medicine vendor ADAC Laboratories continues to be plagued by accounting snafus. The Milpitas, CA, company announced May 19 that it will delay the release of its financial results for the second quarter (end-April) as it evaluates whether
Nuclear medicine vendor ADAC Laboratories continues to be plagued by accounting snafus. The Milpitas, CA, company announced May 19 that it will delay the release of its financial results for the second quarter (end-April) as it evaluates whether to establish additional reserves and one-time charges. The additional reserves are for lower results in Europe and Latin America, while the company did not indicate the reason for the additional charges.
ADAC has been struggling with accounting problems since late 1998, when it announced that it would have to restate revenues for the past three years (SCAN 12/16/98). The news prompted the filing of a half-dozen shareholder lawsuits and caused investors to dump ADAC shares. Last weeks news only exacerbated the situation: ADAC shares were trading at about $8.25 on May 20, down almost 14%.
© 1999 Miller Freeman, Inc.All rights reserved.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
